Nieuws

Applied Clinical Trials Online30 m

NCX 470 Meets Phase III Goal in Glaucoma With Strong Intraocular Pressure Reductions

The Denali trial confirmed non-inferiority of NCX 470 to latanoprost in lowering intraocular pressure, with consistent efficacy, favorable safety, and supportive results from the earlier Mont Blanc ...